Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and adjusted earnings for the first quarter of 2024. First-quarter revenue was $1.62 billion, which is up 5% on a reported basis and 7% at constant currency Women’s Health revenue increased by 11% and Biosimilars revenue climbed ...
alphastreetusx:ogn